6,620
+4.25%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bioneer
Its shares trade on KOSDAQ under the ticker 064550.KQ. It has been listed since 29 December 2005. In the fiscal year to 31 December 2025, it reported revenue of ₩330.11bn and a net loss of ₩2.81bn. At that date it held total assets of ₩369.88bn and shareholders' equity of ₩209.68bn.
BIONEER Corp. engages in the manufacture and sale of biotechnological products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2005-12-29. The firm mainly focuses on the development of deoxyribonucleic acid (DNA) reagents, molecular diagnostic kits and other services, such as DNA and ribonucleic acid (RNA) amplification products, Oligo synthesis and reagents, gene synthesis services, gene expressions, protein expressions and purifications, genomics services, human diagnostics kits, veterinary diagnostics kits and others. The company also provides DNA devices, including DNA extraction, amplification and quantitative analysis devices and other DNA diagnostic devices, and supplies for tests and others. In addition, it provides equipment and supplies used for biotechnology research. The firm operates its business within domestic market and in overseas markets, including America, China, Japan, India, Africa and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Dec 2005
- Website
- bioneer.co.kr ↗
Leadership
Pay as last reported
- Han Oh ParkChief Executive Officer, Director, since 1992
- Jin Pyeong JungHead of Operations Support Division, Director, since 2007
- Jae Ha KimHead of Nano Bio Business, Director
- Jae Don LeeHead of Gene New Medicine Business, Director, since 2007
- Han Yi ParkHead of Gene System Business, Director
- Gyu Yil NahInternal Auditor
- Yong MoonDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bioneer Corp develops DNA reagents and molecular diagnostic kits for global markets including America and China.
- Bioneer Corp provides DNA extraction and amplification devices used in biotechnology research worldwide.
- Bioneer Corp offers gene synthesis services and genomics solutions for human and veterinary diagnostics.
Weaknesses
- Bioneer Corp focuses on domestic market and overseas markets like Africa with limited expansion.
- Bioneer Corp's business is primarily in Health Care sector without diversification into other industries.
- Bioneer Corp's operations are centered in Daejeon, South Korea, limiting global reach.
Opportunities
- Bioneer Corp can expand DNA diagnostic devices into emerging markets such as India and Africa.
- Bioneer Corp can leverage its DNA amplification products for new applications in genomics services.
- Bioneer Corp can increase market share in veterinary diagnostics kits across Asia-Pacific regions.
Threats
- Bioneer Corp faces competition from established biotech firms in America and Japan.
- Bioneer Corp's DNA reagents face regulatory challenges in international markets.
- Bioneer Corp's business is vulnerable to economic downturns in key markets like China and Japan.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.